02 June 2021 : Clinical Research
Nomogram Model for Prediction of Portal Vein Thrombosis in Patients with Liver Cirrhosis After Splenectomy: A Retrospective Analysis of 2 Independent Cohorts
Hai-Liang Yuan1ABCEG, Min Wang2BCDG, Wei-Wei Chu1BDF, Fang-Xian Li1DE, Jing-Jing Lu1DG, Yan Li1ABDE*DOI: 10.12659/MSM.929844
Med Sci Monit 2021; 27:e929844
Table 1 Characteristics of patients in the primary and validation cohorts.
| Primary set (n=219) | Independent validation set (n=96) | |||||
|---|---|---|---|---|---|---|
| PVT (+) | PVT (−) | P value | PVT (+) | PVT (−) | P value | |
| Age (mean±SD, years) | 47.10±9.79 | 46.94±9.89 | 0.476 | 43.10±10.09 | 44.84±9.87 | 0.570 |
| Sex (n [%]) | ||||||
| Male | 48 (67.6) | 89 (60.1) | 0.210 | 12 (75.0) | 49 (61.3) | 0.189 |
| Female | 23 (32.4) | 59 (39.9) | 4 (25.0) | 31 (38.7) | ||
| Etiology (n [%]) | 0.082 | 0.067 | ||||
| HBV | 42 (59.2) | 79 (53.4) | 9 (56.3) | 41 (51.3) | ||
| HCV | 8 (11.3) | 13 (8.8) | 0 (0) | 3 (3.7) | ||
| Alcohol | 13 (18.3) | 39 (26.4) | 4 (25.0) | 19 (23.8) | ||
| Mixed | 8 (11.2) | 17 (11.4) | 3 (18.7) | 17 (21.2) | ||
| DPV (mm) | 15.32±2.41 | 12.36±2.30 | 15.40±2.53 | 11.36±2.82 | ||
| DSV (mm) | 13.93±2.68 | 9.42±2.86 | 13.13±2.08 | 9.72±2.59 | ||
| Child-Pugh class (n [%]) | 0.236 | 0.329 | ||||
| A | 56 (78.9) | 89 (60.1) | 9 (56.2) | 41 (51.3) | ||
| B | 15 (21.1) | 59 (39.9) | 7 (43.8) | 39 (48.7) | ||
| C | – | – | – | – | ||
| BMI (%) (n [%]) | 0.018 | 0.021 | ||||
| 17 (23.9) | 57 (38.5) | 5 (31.3) | 24 (30.0) | |||
| ≥18.5, | 38 (53.5) | 71 (48.0) | 8 (50.0) | 35 (43.8) | ||
| ≥24 | 16 (22.6) | 20 (13.5) | 3 (18.7) | 21 (26.2) | ||
| Surgical method (n [%]) | 0.061 | 0.089 | ||||
| Minimally invasive | 38 (53.5) | 96 (64.9) | 6 (37.5) | 25 (31.3) | ||
| Laparotomy | 33 (46.5) | 52 (35.1) | 10 (62.5) | 55 (68.7) | ||
| ALT (U/L) | 45.9±68.0 | 44.7±56.0 | 0.721 | 43.9±69.2 | 42.7±66.3 | 0.856 |
| AST (U/L) | 53.7±65.0 | 52.8±67.6 | 0.596 | 43.7±61.9 | 42.8±60.2 | 0.467 |
| TBIL (μmol/L) | 21.9±26.2 | 21.7±26.3 | 0.609 | 18.9±28.4 | 19.3±26.8 | 0.789 |
| TP (g/L) | 67.5±7.1 | 65.7±7.6 | 0.073 | 67.5±7.1 | 65.2±7.9 | 0.066 |
| ALB (g/L) | 36.9±6.4 | 39.9±6.5 | 0.017 | 36.3±5.6 | 35.9±7.3 | 0.019 |
| GLB (g/L) | 30.3±6.6 | 26.8±6.4 | 0.013 | 29.2±6.9 | 27.8±5.9 | 0.028 |
| PT (s) | 12.9±2.2 | 12.6±1.9 | 0.890 | 12.3±2.6 | 11.8±2.7 | 0.796 |
| PTA (%) | 83.5±24.8 | 83.7±21.9 | 0.498 | 82.9±23.9 | 83.3±20.6 | 0.317 |
| APTT (s) | 32.3±8.1 | 31.9±7.6 | 0.159 | 31.6±9.1 | 31.9±8.2 | 0.238 |
| INR | 1.2±0.3 | 1.1±0.4 | 0.316 | 1.0±0.6 | 1.1±0.4 | 0.561 |
| D-dimer (μg/L) | 2.5±2.7 | 2.6±1.6 | 0.367 | 2.7±2.8 | 2.6±2.9 | 0.469 |
| PLT (×10/L) | 215.1±161.7 | 160.1±138.2 | 209.1±160.6 | 170.6±142.8 | ||
| value is derived from the univariate association analyses between the training group and validation group. SD – standard deviation; PVT – portal vein thrombosis; HBV – hepatitis B virus; HCV – hepatitis C virus; DPV – diameter of portal vein; DSV – diameter of splenic vein; BMI – body mass index; ALT – alanine aminotransaminase; AST – aspartate aminotransaminase; TBIL – total serum bilirubin; DBIL – direct serum bilirubin; TP – total serum protein; ALB – serum albumin; PT – prothrombin time; PTA – prothrombin activity; APTT – activated partial thromboplastin time; INR – international normalized ratio; PLT – platelet count. | ||||||